Independent Advisor Alliance Raises Holdings in Amgen Inc. $AMGN

Independent Advisor Alliance grew its position in Amgen Inc. (NASDAQ:AMGN) by 8.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,341 shares of the medical research company’s stock after buying an additional 2,785 shares during the quarter. Independent Advisor Alliance’s holdings in Amgen were worth $11,568,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares during the period. Anfield Capital Management LLC lifted its holdings in shares of Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Amgen in the 4th quarter worth $26,000. Manning & Napier Advisors LLC lifted its holdings in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC purchased a new stake in shares of Amgen in the 4th quarter worth $33,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Daiwa Securities Group upped their target price on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Guggenheim lowered their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a report on Monday, May 4th. The Goldman Sachs Group upped their price objective on Amgen from $415.00 to $425.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Wells Fargo & Company upped their price objective on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $350.00 price objective on shares of Amgen in a research note on Wednesday, April 8th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $357.12.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.85% of the stock is currently owned by insiders.

Amgen Trading Up 2.0%

Shares of NASDAQ AMGN opened at $336.29 on Wednesday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock has a market capitalization of $181.49 billion, a P/E ratio of 23.40, a price-to-earnings-growth ratio of 3.31 and a beta of 0.44. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The business has a fifty day moving average price of $352.03 and a 200 day moving average price of $342.49.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts expect that Amgen Inc. will post 22.36 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.0%. Amgen’s dividend payout ratio is presently 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.